The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer
CONCLUSION: Low-dose apatinib combined with oral vinorelbine demonstrates potential efficacy and well tolerated for pretreated HER2-negative mBC.PMID:38659376 | DOI:10.1002/cam4.7181 (Source: Cancer Control)
Source: Cancer Control - April 25, 2024 Category: Cancer & Oncology Authors: Jia-Yi Huang Xue-Lian Chen Xiao-Feng Xie Lin Song Li-Ping Chen Xiao-Feng Lan Xue Bai Xiao Chen Cai-Wen Du Source Type: research
The efficiency and safety of low ‐dose apatinib combined with oral vinorelbine in pretreated HER2‐negative metastatic breast cancer
ConclusionLow-dose apatinib combined with oral vinorelbine demonstrates potential efficacy and well tolerated for pretreated HER2-negative mBC. (Source: Cancer Medicine)
Source: Cancer Medicine - April 25, 2024 Category: Cancer & Oncology Authors: Jia ‐Yi Huang,
Xue‐Lian Chen,
Xiao‐Feng Xie,
Lin Song,
Li‐Ping Chen,
Xiao‐Feng Lan,
Xue Bai,
Xiao Chen,
Cai‐Wen Du Tags: RESEARCH ARTICLE Source Type: research
Cancers, Vol. 16, Pages 1651: Liver X Receptor Ligand GAC0001E5 Downregulates Antioxidant Capacity and ERBB2/HER2 Expression in HER2-Positive Breast Cancer Cells
In this study, HER2-positive breast cancer cells were treated with 1E5 to determine their potential inhibitory effects and mechanisms of action in HER2-positive breast cancers. Similar to previous observations in other cancer types, 1E5 treatments inhibited LXR activity, expression, and cancer cell proliferation. Expression of fatty acid synthesis genes, including fatty acid synthase (FASN), was downregulated following 1E5 treatment, and results from co-treatment experiments with an FASN inhibitor suggest that the same pathway is targeted by 1E5. Treatments with 1E5 disrupted glutaminolysis and resulted in increased oxidat...
Source: Cancers - April 25, 2024 Category: Cancer & Oncology Authors: Asitha Premaratne Shinjini Basu Abhinav Bagchi Tianyi Zhou Qin Feng Chin-Yo Lin Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1649: The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy & mdash;A Retrospective Multi-Center Cohort Study
We report here a systematic review, as well as a retrospective multi-center study of 17 patients with triple-negative breast cancer who received concurrent SG and radiotherapy. In these patients, concurrent use was found to be efficient, safe and well tolerated. There were no apparent differences in moderate or severe acute toxicity according to the timing of SG administration. (Source: Cancers)
Source: Cancers - April 25, 2024 Category: Cancer & Oncology Authors: David Krug Joke Tio Ali Abaci Bj örn Beurer Sandra Br ügge Khaled Elsayad Eva Meixner Tjoung-Won Park-Simon Katharina Smetanay Franziska Winkelmann Andrea Wittig Achim W öckel Tags: Article Source Type: research
Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey
ConclusionTrials to investigate who can safely and effectively be treated with shorter durations of anti-HER2 therapy are needed. This study provides important insights to patients ’ perspectives on shorter durations of anti-HER2 treatment, and their concerns regarding potential increased cancer risk with less treatment. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 25, 2024 Category: Cancer & Oncology Source Type: research
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Cancer Research - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
GSE249574 Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies
Series Type : Genome binding/occupancy profiling by high throughput sequencing ; Expression profiling by high throughput sequencingOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE249573 Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies [RNA-seq]
Contributors : Kornelia Polyak ; Marie-Anne Goyette ; Laura StevensSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensIn a 3D coculture with stroma cells derived from breast cancer patients ’ brain metastasis, HER2+ breast cancer cells were protected from HER2-targeted therapies, particularly the EGFR/HER2 small molecule inhibitor neratinib. To get insight into how this protection arises, a Synthetic Notch (SynNotch) reporter model allowed to study the effect of direct contact betwee n stroma and cancer cells. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE249459 Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies [ATAC-seq]
Contributors : Kornelia Polyak ; Marie-Anne Goyette ; Laura StevensSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensIn a 3D coculture with stroma cells derived from breast cancer patients ’ brain metastasis, HER2+ breast cancer cells were protected from HER2-targeted therapies, particularly the EGFR/HER2 small molecule inhibitor neratinib. To get insight into how this protection arises, ATAC-seq on coculture cells with or without neratinib as performed. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
ConclusionsIn our cohort, HER2-low TNBC patients exhibits specific clinical characteristics and response features to NAC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 24, 2024 Category: Cancer & Oncology Source Type: research
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.PMID:38652877 | DOI:10.1200/JCO.23.01909 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Ian E Krop Takahiro Kogawa Dejan Juric Anthony W Tolcher Erika P Hamilton Toru Mukohara Aaron Lisberg Toshio Shimizu Alexander I Spira Junji Tsurutani Senthil Damodaran Kyriakos P Papadopoulos Jonathan Greenberg Fumiaki Kobayashi Hong Zebger Source Type: research
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.PMID:38652877 | DOI:10.1200/JCO.23.01909 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Ian E Krop Takahiro Kogawa Dejan Juric Anthony W Tolcher Erika P Hamilton Toru Mukohara Aaron Lisberg Toshio Shimizu Alexander I Spira Junji Tsurutani Senthil Damodaran Kyriakos P Papadopoulos Jonathan Greenberg Fumiaki Kobayashi Hong Zebger Source Type: research
Brystkreft hos menn – histopatologi og biomarkører
Tidsskr Nor Laegeforen. 2024 Mar 27;144(5). doi: 10.4045/tidsskr.23.0438. Print 2024 Apr 23.ABSTRACTBACKGROUND: Breast cancer in men accounts for around 1 % of all cases of the disease. The study aimed to identify histopathological parameters and selected biomarkers in men with breast cancer.MATERIAL AND METHOD: Retrospective study of archival material from 53 men diagnosed with breast cancer at the department of pathology, Haukeland University Hospital, in the period 1996-2020. The prevalence of the oestrogen receptor (ER), progesterone receptor (PGR) and Human Epidermal Growth Factor (HER2) biomarkers was examined.RESULT...
Source: Tidsskrift for den Norske Laegeforening - April 23, 2024 Category: General Medicine Authors: Ingvild Kathrin Lok øy Inga Sofie Bakken Elisabeth Wik Ingunn Marie Stefansson Source Type: research
A ratiometric electrochemical biosensor based on ARGET ATRP for detection of HER2 gene
Talanta. 2024 Apr 22;275:126130. doi: 10.1016/j.talanta.2024.126130. Online ahead of print.ABSTRACTHuman epidermal growth factor receptor 2 (HER2), a common proto-oncogene, is overexpressed in a subset of breast cancer patients. It is essential to track HER2 expression for early breast cancer diagnosis. Herein, a ratiometric electrochemical biosensor for detection of HER2 based on activators generated by electron transfer for atom transfer radical polymerisation (AGET ATRP) and hairpin DNA was developed. Specifically, hairpin DNA was first self-assembled on the gold electrode by Au-S bond. Upon capturing HER2, the stem-loo...
Source: Talanta - April 23, 2024 Category: Chemistry Authors: Aozi Feng Li Li Ningxia He Daoxiang Li Danna Zheng Yanju Liu Huaixia Yang Source Type: research
